Page 3 - Development Highlights News Today

Theodore roosevelt from outside new yorks museum of Natural History. Fox friendfox friends cot now. Jillian a very good monday morning to you. You are watching fox friends first. Im jillian mele. Rob im rob schmitt. We begin with a fox news alert. More violence inside seattles chop zone overnight as at least one person is shot. More shots fired. Im running away. Rob thats the situation there. Fox news is told the victim is in serious condition at a hospital right now in seattle and it all comes ...

Endeavour Silver Corp. provided a first quarter of 2024 construction progress update for its Terronera Project in Jalisco state, Mexico. First quarter 2024 Construction and Development Highlights: As...

Real-Time News, Market Data and Stock Quotes For Junior Mining Stocks.

WAYNE, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the fourth quarter and full year of 2023 and provided a corporate update. “As we enter 2024, we are financially strong, focused and motivated,” stated Dr. Neal Walker, co-founder and Interim Chief Executive Officer & President of...

ColoAlert® Revenue Increases 102% Year Over Year for the Nine Months Ended September 30, 2023ColoFuture Study Reported Groundbreaking Results Demonstrating Sensitivity for Colorectal Cancer of 94%...

Focus on executing the strategic plan and delivering shareholder valueFirst MDG2011 pre-clinical data support potential in solid tumor therapyExpansion of patent portfolio and license agreement for...

FTI Consulting is pleased to share our third annual Corporate Sustainability Report. Within our report, we share our approach to addressing our…

Dublin, Oct. 11, 2023 (GLOBE NEWSWIRE) -- The

Pipeline expansion into neoantigens with multiple KRAS mutations as the first targetsAcquired exclusive, worldwide rights to a CD40L-CD28 costimulatory switch proteinData from MDG1015 and multiple TCRs combined with PD1-41BB costimulatory

Phase 3 LUMEOS clinical trial of botaretigene sparoparvovec (bota-vec, formerly AAV-RPGR) for the treatment of X-linked retinitis pigmentosa (XLRP) enrollment target has now been surpassedAnnounced positive clinical data from the completed AQUAx Phase 1 study of AAV2-hAQP1 for the treatment of grade 2/3 radiation-induced xerostomia (RIX), showing bilaterally treated participants reaching normal levels of whole saliva flow rate by 2 months post-treatment and persisting through the final Month 12